Clinical trials: Cetuximab
Head and Neck Squamous Cell Carcinoma
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- HNSCC (NCT06332092)
- Testing
- FID007
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Fulgent Pharma LLC.
Head and Neck Cancer
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
This is a study for patients who have head and neck cancer that has recurred in the body area where they previously received radiation, and for whom surgery is not planned.
- Trial name
- NCT00713219
- Testing
- IMRT, cetuximab, docetaxel
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Carcinoma, Squamous
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size
- Trial name
- NCT00591149
- Testing
- Oxaliplatin, Docetaxel, Cetuximab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Kansas Medical Center
Bladder Cancer
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
- Trial name
- NCT00645593
- Testing
- Gemcitabine,, Cisplatin, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gastric Cancer
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction (GEJ) who have not previously received…
- Trial name
- NCT01388790
- Testing
- Cetuximab, Cisplatin, S-1
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colon Cancer, Locally Advanced Malignant Neoplasm
Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
In patients with locally advanced colon cancer (high risk stage II and stage III), curative surgery followed by adjuvant FOLFOX-4 chemotherapy has become the standard of care.
- Trial name
- ECKINOXE (NCT01675999)
- Testing
- Perioperative simplified FOLFOX-4 chemotherapy, Perioperative FOLFOX4+Cetuximab chemotherapy, Surgery followed by FOLFOX4 chemotherapy
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Mucinous Gastrointestinal Adenocarcinoma
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.
- Trial name
- NCT00162110
- Testing
- cetuximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer Metastatic
Colorectal Cancer (CRC) Cetuximab Elderly Frail
OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free…
- Trial name
- NCT01522612
- Testing
- Cetuximab, 5-fluorouracil, leucovorin
- Where
- 3 sites in Belgium, Cyprus and 1 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
A Study of BND-35 in Participants With Advanced Solid Tumors
This is an open-label, multicenter, dose escalation and dose optimization study designed to evaluate safety, tolerability and preliminary anti-tumor activity of BND-35 administered alone and in combination with nivolumab or with…
- Trial name
- NCT06274437
- Testing
- BND-35, Nivolumab, Cetuximab
- Where
- 5 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Biond Biologics
Metastatic Colorectal Cancer (CRC)
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
This study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies.
- Trial name
- ROMANCE - GOIM (NCT07381764)
- Testing
- Erbitux (Cetuximab), Bevacizumab, Irinotecan
- Where
- 26 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Oncologico Italia Meridionale
Colorectal Cancer, Non-Small Cell Lung Cancer
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
- Trial name
- NCT05954871
- Testing
- GDC-1971, Osimertinib, Cetuximab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer Metastatic
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3…
- Trial name
- VISNU-2 (NCT01640444)
- Testing
- FOLFIRI + bevacizumab, FOLFIRI + cetuximab
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Gastric Cancer
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer
RATIONALE: Radiotherapy is currently the most efficient way to induce pathologic responses, which are associated with a favorable prognosis in localized tumors.
- Trial name
- NCT01611506
- Testing
- Cetuximab, Capecitabine, Cisplatin
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Dr Anna Dorothea Wagner
Breast Cancer
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".
- Trial name
- NCT00600249
- Testing
- Cetuximab, Docetaxel
- Where
- 6 sites in France
- Volunteers
- 35 people
- Sponsor
- Centre Jean Perrin
Neoplasm Metastasis, Colorectal Cancer
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor…
- Trial name
- OPUS (NCT00125034)
- Testing
- Cetuximab, Oxaliplatin
- Where
- 78 sites in Austria, Belgium and 11 more
- Volunteers
- 344 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00551421
- Testing
- pertuzumab, cetuximab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon…
- Trial name
- NCT00077233
- Testing
- cetuximab, 5-FU, irinotecan
- Where
- 77 sites in United States
- Volunteers
- 238 people
- Sponsor
- Alliance for Clinical Trials in Oncology